Drugs / Amuvatinib
Amuvatinib
also known as
MP-470 · AMUVATINIB HYDROCHLORIDE · HPK 56 · HPK56 HCL · MP-470 HCI · MP-470 HYDROCHLORIDE · MP-470.HCL
Small molecule targets FLT3, KIT, MET, PDGFRA, RAD51 via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00881166 | Nov 2007 → Dec 2009 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00894894 | May 2007 → Dec 2008 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01357395 | May 2011 → May 2012 | small cell lung carcinoma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00504205 | May 2007 → Dec 2008 | cancer of unknown primary site, lymphoma | Astex Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2012-09-21 | Astex Pharmaceuticals, Inc. | Results Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program astx.com ↗
Response evaluation by RECIST criteria showed 2 partial responses in the 21 evaluable patients of stage 1 (9.5% Response Rate). |
| 2009-08-03 | Astex Pharmaceuticals, Inc. | Results SuperGen’s MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients astx.com ↗
There were no clinically significant adverse events attributable to the addition of MP-470 to SOC. |
| 2009-05-04 | Astex Pharmaceuticals, Inc. | Results SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients astx.com ↗
Of eleven evaluable patients, only one showed progressive disease, five showed stable disease, and five showed partial response. |
| 2009-04-13 | Astex Pharmaceuticals, Inc. | Results SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting astx.com ↗
The poster presentations will focus on data concerning many of SuperGen ’s current oncology programs, including the lead clinical compound, MP -470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents. |
| 2008-10-23 | Astex Pharmaceuticals, Inc. | Results SuperGen’s MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy astx.com ↗ |
| 2008-08-07 | Astex Pharmaceuticals, Inc. | Regulatory SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme astx.com ↗
SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. |
| 2008-04-15 | Astex Pharmaceuticals, Inc. | Results Data Show SuperGen’s MP-470 is Safe in Humans astx.com ↗ |
| 2008-04-14 | Astex Pharmaceuticals, Inc. | Results SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib astx.com ↗
SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that MP -470 effectively sensitizes prostate and breast cancer cells to erlotinib (Abstract No. 671). |
| 2007-10-31 | Astex Pharmaceuticals, Inc. | Results Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme astx.com ↗
Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. |
| 2007-10-25 | Astex Pharmaceuticals, Inc. | Results Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents astx.com ↗
MP470, a multi-targeted tyrosine kinase inhibitor, demonstrated synergy with DNA damaging agents, including platinum based treatments, topoisomerase inhibitors, nucleoside analogs and the targeted agent erlotinib. |
| 2007-10-17 | Astex Pharmaceuticals, Inc. | Results SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference astx.com ↗ |
| 2007-04-27 | Astex Pharmaceuticals, Inc. | Regulatory SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 astx.com ↗
SuperGen Inc. (Nasdaq: SUPG - News) today announced that the Food and Drug Administration cleared MP470, a novel oral multi -targeted tyrosine kinase inhibitor (TKI), for a first -in-human Phase I clinical trial. |
| 2007-04-19 | Astex Pharmaceuticals, Inc. | Results Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 astx.com ↗ |
| 2007-04-04 | Astex Pharmaceuticals, Inc. | Results SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR astx.com ↗ |
All press releases naming this drug 14 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amuvatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357395 ↗ |
| Known as | AMUVATINIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | HPK 56 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | HPK56 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00881166 ↗ |
| Known as | MP-470 HCI | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470.HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Action | Inhibit | “MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT00504205 ↗3“Platelet-derived growth factor receptor alpha inhibitor” CHEMBL2103851 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL2103851 ↗ “Hepatocyte growth factor receptor inhibitor” CHEMBL2103851 ↗ |
| Modality | Small molecule | — CHEMBL2103851 ↗ |
| Route | Oral | “Patients receive oral multitargeted receptor tyrosine kinase inhibitor MP470 until the maximum tolerated dose is determined.” NCT00504205 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL2103851 ↗ |
| Target | KIT | “in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51” PMID 23178951 ↗ Nov 2012 |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL2103851 ↗ |
| Target | PDGFRA | “Platelet-derived growth factor receptor alpha inhibitor” CHEMBL2103851 ↗ |
| Target | RAD51 | “in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51” PMID 23178951 ↗ Nov 2012 |